In order to compare the difference between young and old intervertebral disc cells and their responsiveness to recombinant human bone morphogenetic protein-2 (rhBMP-2), disc cells were isolated from the anulus fibrosus (AF) and transition zones of lumbar discs from eight old and eight young New Zealand white rabbits. Compared with the cells from the young rabbits, cells from old rabbits respond less to rhBMP-2 treatment with respect to sulfated-glycosaminoglycan (sGAG) synthesis and aggrecan gene expression. But in collagen I and collagen II gene expressions, there are no significant differences between the old and the young. When comparing sGAG content, aggrecan, and collagen II gene expression of the old AF cells after rhBMP-2 treatment with that of the young AF cells without rhBMP-2 treatment, the old AF cells with rhBMP-2 treatment have a greater capacity to synthesize sGAG bound in the cells and to release sGAG in the media, as well as to express aggrecan and collagen II gene. It can be concluded that old AF cells after rhBMP-2 treatment have a greater capacity to synthesize sGAG and express aggrecan and collagen II as compared to young AF cells without rhBMP-2 treatment. Thus rhBMP-2 can reverse the decline in the anabolic capacity of the disc cells with ageing. So it seems that rhBMP-2 has potential for use as an agent to retard a key component of disc degeneration and loss of disc matrix.
Several anabolic cytokines, such as transforming growth factor-β (TGF-β), bone morphogenetic protein-2 (BMP-2), bone morphogenetic protein-4 (BMP-4), bone morphogenetic protein-6 (BMP-6), osteogenic protein-1 (OP-1, BMP-7), insulin-like growth factor (IGF), fibroblast growth factor (FGF), epithelial growth factor (EGF), and platelet-derived growth factor (PDGF) have been found in normal and degenerated intervertebral discs [1] . Some of these anabolic cytokines have subsequently been used for in vitro experiments as stimuli for cell proliferation and matrix synthesis. Thompson et al. were among the first to study the effect of growth factors including IGF-I, EGF, FGF, TGF-β on mature canine intervertebral disc tissue. The anulus, the transition zone, and the nucleus were all responsive to EGF, TGF-β, FGF, and a lesser extent to IGF-I [2] . Masuda et al. reported the stimulatory effect of recombinant human OP-1 on proteoglycan and collagen metabolism in rabbit nucleus pulposus and anulus fibrosus (AF) cells. In both cell types, OP-1 stimulated the synthesis of proteoglycans and collagens in a dose-dependent manner (50−200 ng/ml) with an associated increase in the expression of mRNA for aggrecan and collagen II [3] . Yoon et al. showed that recombinant human BMP-2 (rhBMP-2) increased rat AF cell proliferation and proteoglycan synthesis in a dose-dependent manner (10−1000 ng/ml). In the same experiment, rhBMP-2 was shown to increase collagen II, aggrecan, and Sox9 mRNA levels [4] . The experiment of Li et al. using rat AF cells showed that rhBMP-2 at 200 ng/ml significantly increased the release of proteoglycans and collagen II into the culture media, as well as the mRNA level of these molecules [5] .
There are a few of reports on the age-related changes of intervertebral disc matrix metabolism and changes in responsiveness to anabolic cytokines. Okuda et al. reported the age-related decline in IGF-I-dependent proteoglycan synthesis in rat nucleus pulposus cells [6] . Matsumoto et al. showed that the capacity of bovine nucleus pulposus and AF cells to synthesize proteoglycans decreases with age, although both old and young bovine disc cells respond similarly to OP-1 [7] . Hitherto there have been no reported studies comparing the difference between young and old intervertebral disc cells and their responsiveness to rhBMP-2.
We therefore decided to carry out such an experiment. We hope that the results of this experiment will help us further verify whether rhBMP-2 can be used to retard disc degeneration in vivo. Before moving to an in vivo experiment, we need to know whether rhBMP-2 has the capacity to stimulate both young and, in particular, old disc cells.
Materials and Methods

Materials
Protease was purchased from Sigma Chemical (St. Louis, USA). Collagenase P was from Roche (Indianapolis, USA). Dulbecco's modified Eagle's medium and Ham's F-12 medium (DMEM/F-12) were from Cellgro, Mediatech Inc. (Herndon, USA). rhBMP2 was from Genetic Institute (Cambridge, USA). Hoechst dye 33258 was from Polysciences (Washington, USA). RNeasy mini kit and DNase I were from Qiagen Inc. (Valencia, USA). Reverse transcription reagents and SYBR Green real-time PCR kit were purchased from Applied Biosystems (Foster City, USA).
Disc cell isolation
Sixteen New Zealand White rabbits with Atlanta Veteran's Administration Medical Center (VAMC) Institutional Animal Care and Use Committee approval was obtained. There were eight young rabbits (six months old), and eight old rabbits (three years old). Six lumbar intervertebral discs from each rabbit (L1-2, L2-3, L3-4, L4-5, L5-6, L6-7) were harvested immediately after they were euthanized. AF including transition zone was dissected out and diced. The cells were isolated using 0.2% protease digestion for 1 h and 0.025% collagenase P digestion overnight in DMEM/F-12 with 10% fetal bovine serum (FBS), 100 U/ml penicillin G, 100 μg/ml streptomycin and 0.25 μg/ml amphotericin B (Cellgro, Mediatech Inc.) in a 37 ºC incubator with 5% CO 2 . At the end of digestion, the cells were recovered by filtration through a cell strainer and centrifugation. After counting using a hemocytometer, the cells were cultured in T-75 cell culture flasks with DMEM/F-12 medium containing 10% FBS, the antibiotic mentioned above and 50 μg/ml ascorbate. The culture medium was refreshed every 2 days [5] .
AF cells, rather than nucleus pulposus cells, were chosen for this experiment. We found that it is difficult to get enough nucleus pulposus cells to do these experiments.
Recombinant human BMP-2 (rhBMP-2) treatment
After being grown to confluence in T-75 cell culture flasks, the primary cells were trypsinized and sub-cultured in 6-well plates at 200,000 cells per well. Three days later, when the cultures in each well were over 80% confluence, the media were replaced with DMEM/F-12 containing 1% FBS. rhBMP-2 was added to the media to reach a final concentration of 100 ng/ml. The dose of 100 ng/ml was a moderate dose that would produce a beneficial effect without making bone in the disc according to our earlier experiments [4] . Cultures without rhBMP-2 treatment were taken as controls. Another three days later, the cells and culture media were harvested respectively (one well each sample) for DNA assay, sulfated-glycosaminoglycan (sGAG) assay and RNA extraction (two wells each sample). A three days treatment was chosen because the phenotype of cells would change if the cells were cultured in monolayer for a long time.
DNA assay
Cell number was calculated according to the DNA content in each well. The DNA content was measured using a Hoechst dye 33258 method [8] . Cultured cells were collected and digested with papain (10 U/ml) at 60 ºC for 3 h. Ten microliters of the papain digest was then mixed with 200 μl of diluted Hoechst dye 33258 solution in a 96-well fluoroplate. Emission and excitation spectra were measured in Luminescence Spectrometer LS 50B (PerkinElmer, Wellesley, USA) at 456 nm and 365 nm, respectively. Standard curves were generated at the time of each measurement using known concentrations of calf thymus DNA (Sigma Chemical). Each sample was measured three times.
Sulfated-glycosaminoglycan assay
The sGAG content of the culture media and the sGAG bound in the cells were assayed using the modified 1,9-775 http://www.abbs.info; www.blackwellpublishing.com/abbs dimethylmethylene blue (DMMB) method as previously described [9] . One hundred micrograms of culture medium was mixed gently with 200 μl of DMMB dye solution in a 96-well microtiter plate, and the absorbance was measured immediately at 520 nm. A standard curve was constructed using serial dilutions of chondroitin sulfate (Sigma Chemical). The sGAG bound in the cells was determined using 10 μl of papain digested sample with 200 μl of DMMB dye solution. Each sample was measured three times. Total sGAG is expressed as the sGAG in the culture medium plus the sGAG bound in the cells. They were all normalized by DNA content and presented as a ratio to the untreated control when calculating response.
RNA and cDNA preparation
Total RNA of each sample was extracted using an RNeasy mini kit following the RNeasy mini protocol for isolation of total RNA from animal cells. The RNA was treated with DNase I to remove DNA contamination of the samples. The concentration of the isolated RNA was determined with a DU-500 spectrophotometer (Beckman, Fullerton, USA) at 260 nm. The ratio of absorbance at 260 nm versus 280 nm was between 1.6 and 1.8. Reverse transcription (RT) was carried out in a total volume of 100 μl with 1 μg of total RNA including 10 μl of 10×RT buffer, 22 μl of 25 mM MgCl 2 , 20 μl of 10 mM dNTP mixture, 0.5 μl of 50 μM oligo(dT), 0.5 μl of 50 μM random primer, 2 μl of 20 U/μl RNase inhibitor and 2.5 μl of 50 U/μl MuLV reverse transcriptase for 10 min at 25 ºC, 30 min at 48 ºC, 5 min at 95 ºC. To confirm the absence of DNA contamination, RNA samples treated without reverse transcriptase were also subjected to PCR. The absence of PCR product ruled out the possibility of DNA contamination.
Quantitative real-time polymerase chain reaction
An SYBR Green real-time PCR kit was used to quantify the mRNA of aggrecan, collagen II, collagen I, BMP-2, BMP-2 receptor IA (BMP2R-IA) and 18S RNA. The total reaction volume was 25 μl including 5 μl of cDNA, 5 pmol of each primer, and 12.5 μl of SYBR Green 2×master mix (Applied Biosystems). The primer sequences are listed in Table 1 . Real-time PCR was performed with the following three-step protocol: step 1, 50 ºC for 2 min; step 2, 95 ºC for 10 min; and step 3, 40 cycles of 95 ºC for 15 s and 62 ºC for 1 min. The Gene Amp 5700 sequence detection system (Applied Biosystems) was used. To confirm amplification specificity, the PCR products were subjected to a dissociation curve analysis. Threshold cycle (Ct) of each reaction was standardized according to 18S Table 1 Primer sequences for aggrecan, collagen II, collagen I, BMP-2 and BMP2R-IA Primer Sequence
RNA using the comparative 2 −ΔΔCt method, as described previously [10] .
Statistical analysis
Two-tailed Student t tests were used to compare the normalized results obtained from the young rabbits, with those obtained from the old rabbits. The error bars in the figures present the standard error of the mean (SEM). P value of less than 0.05 was used to define statistical significance.
Results
Aggrecan, collagen II and collagen I gene expression distribution
Both young and old AF cells showed higher levels of collagen I gene expression (young, 33.98±14.14; old, 11.16±3.47) compared to collagen II gene expression (young, 6.12±3.48; old, 1.60±0.92) and aggrecan gene expression (young, 0.98±0.05; old, 0.95±0.07) (Fig. 1) . There were significant differences between young and old for both collagen I and collagen II gene expression, but not for aggrecan gene expression. The proportional distribution between collagen I, collagen II, and aggrecan gene expression was similar between the young and old AF cells. In the comparisons described in this section we normalized against the values for "aggrecan" individually.
Sulfated-glycosaminoglycan content and the response to rhBMP-2
With respect to sGAG bound in the cells, there was no difference between young and old (young, 1.71±0.17; old, for, forward; rev, reverse.
1.74±0.21) ( Table 2 , row 2). With respect to sGAG in the culture media, there was significant difference (young, 2. 01±0.16; old, 2.79±0.10) ( Table 2 , row 3) with more sGAG released into the cell media in the old AF cells. After 3 d of treatment with 100 ng/ml rhBMP-2, the situation was reversed. The young AF cells increased their sGAG content greater than the old AF cells after rhBMP-2 treatment, especially the sGAG bound in the cells. The young AF cells increased sGAG bound in the cells from 1.71±0.17 to 2.87±0.23 (Table 2, row 2); and the old AF cells increased sGAG bound in the cells from 1.74±0.21 to 2.36±0. 22 ( Table 2 , row 2). The difference of response to rhBMP-2 between the young and the old AF cells was significant (Fig. 2) . Thus the young AF cells responded better to the rhBMP-2 than the old AF cells, with respect to sGAG synthesis.
Comparison between the old anulus fibrosus cells and the young anulus fibrosus cells before rhBMP-2 treatment
The young AF cells showed significantly higher levels of collagen II and collagen I gene expression than the old AF cells (collagen II: young, 0.96±0.06, old, 0.63±0.08; collagen I: young, 1.18±0.08, old, 0.47±0.06) ( Table 3 , row 2 and 3). For aggrecan gene expression, there was no significant difference between the young and the old cells (young, 0.98±0.05; old, 0.95±0.07) ( Table 3 , row 1). Conversely, the old AF cells showed significantly higher levels of gene expression for BMP-2 (young, 1.01±0.00; old, 2.77±0.76) ( Table 3 , row 4) and BMP2R-IA (young, 1.01±0.01; old, 1.49±0.19) ( Table 3 , row 5). In the comparisons described in this section we normalized against the values for "young" each time.
The effect of rhBMP-2 on aggrecan, collagen II, and collagen I gene expression
The young AF cells responded better to rhBMP-2 for aggrecan. In the young AF cells, aggrecan gene expression was up-regulated from 0.98±0.05 to 4.51±0.40 (i.e., 4.6 folds) ( Table 3 , row 1); but in the old AF cells, it was up-regulated from 0.95±0.07 to 3.02±0.37 (i.e., 3.2 folds) ( Table 3 , row 1). The difference between 4.6 and 3.2 was statistically significant [ Fig. 3(A) ]. For collagen II gene expression, it was increased from 0.96±0.06 to Cellular sGAG is the sGAG bound in the cells; medium sGAG is the sGAG in the culture media; total sGAG is cellular sGAG plus medium sGAG. The sGAG content values were normalized by DNA content (μg sGAG/μg DNA). Data are shown as mean±SEM (n=8). Young, the group of young AF cells; Young+rhBMP-2, the group of young AF cells incubated with rhBMP-2. Old, the group of old AF cells; old+rhBMP-2, the group of old AF cells incubated with rhBMP-2.
Fig. 2
The response to recombinant human bone morphogenetic protein-2 (rhBMP-2) for sulfated-glycosaminoglycan (sGAG) sGAG content was normalized by DNA content first, then presented as a ratio of comparison between rhBMP-2 treatment and control. Data are shown as mean±SEM (n=8). * the difference of response to rhBMP-2 between the young and the old AF cells was significant.
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http://www.abbs.info; www.blackwellpublishing.com/abbs 2.00±0.33 (i.e., 2.1 folds) ( Table 3 , row 2) in the young AF cells; from 0.63±0.08 to 1.06±0.09 (i.e., 1.7 folds) ( Table 3 , row 2) in the old AF cells. But the difference between 2.1 and 1.7 was not statistically significant [ Fig.  3(B) ]. Collagen I gene expression was depressed by rhBMP-2 in young AF cells (from 1.18±0.08 to 0.71±0.10, i.e., 0.6 fold) ( Table 3 , row 3) and in old AF cells (from 0.47± 0.06 to 0.40±0.09 (i.e., 0.8 fold) ( Table 3 , row 3), with the old AF cells seems less depressed. But the difference between 0.6 and 0.8 was not statistically significant [ Fig. 3(C) ].
Comparison between the old anulus fibrosus cells with rhBMP-2 treatment with the young anulus fibrosus cells without rhBMP-2 treatment
When comparing sGAG content, aggrecan, and collagen II gene expression of the old AF cells after rhBMP-2 treatment with the young AF cells without rhBMP-2 treatment, the old AF cells with rhBMP-2 treatment showed a higher ability to synthesize sGAG bound in the cells (2.36±0.22 versus 1.71±0.17, significant) and to release sGAG in the media (4.82±0.29 versus 2.01±0.16, significant) as well as to express aggrecan and collagen II genes (aggrecan gene: 3.02±0.37 versus 0.98±0.05, significant; collagen II: 1.06±0.09 versus 0.96±0.06, not significant).
Discussion
The most important result from this experiment on AF cells from young and old rabbits is that old AF cells after rhBMP-2 treatment had a greater capacity to synthesize and release sGAG, as well as to express aggrecan and collagen II genes as compared to the young AF cells without rhBMP-2 treatment. Thus rhBMP-2 can reverse the decline in the anabolic capacity of the disc cells with ageing. Or, in other words, it can make old cells behave as young cells. So it seems that rhBMP-2 has the potential to reverse an important aspect of disc degeneration (i.e., counteract the decrease in synthesis of chondrogenic disc matrix).
The other results from these experiments are: (i) although there were significant differences between young and old for both collagen I and collagen II gene expression, the Collagen I and collagen II are the most abundant collagens in the disc, accounting for about 70%−80% of the total collagen. Collagen I is found mainly in the outer anular region, and collagen II is present at highest concentrations within the nucleus. The disc also possesses a variety of proteoglycans in its extra-cellular matrix, including aggrecan, versican, decorin, byglycan, fibromodulin, and lumincan, with aggrecan being by far the most abundant proteoglycan on a weight basis. In a mature disc, aggrecan presents both in the nucleus pulposus and AF and possesses both chondroitin sulfate and keratan sulfate chains bound to the same core protein [11] . In this study, it was shown that the proportional distribution of collagen I, collagen II and aggrecan gene expression is similar between young and old rabbits. Although the extent of gene expression was reduced with age, the proportional matrix gene distribution between collagen I, collagen II and aggrecan was maintained.
Our study shows that there was no difference of aggrecan gene expression and sGAG bound in the cells between the young and the old cells, but the old AF cells deposited more sGAG into the culture media. Maeda et al. [12] studied the proteoglycan synthesis and release in anulus cells from young and old rabbits and their response to IL-1 and IL-1 receptor antagonist. They showed that proteoglycan synthesis significantly decreased and the release rate significantly increased in the old rabbit cells. Cs-Szabo et al. [13] studied 34 human lumbar discs that were graded by Thompson's morphologic scale, and found that in AF, the mRNA and protein content of all proteoglycans were significantly elevated at the early stages of degeneration but subsequently declined in severe degeneration. They concluded that cells of AF and nucleus pulposus react to tissue degeneration differently; the cells in AF respond to early degeneration by up-regulating the biosynthetic processes. We found that the total sGAG was elevated in our 3-year-old rabbits at the early stages of disc degeneration.
The other two major matrix components in the intervertebral disc are collagen I and collagen II. In the study presented here there were significant differences in collagen I and collagen II basal gene expressions between young and old AF cells. Goudsouzian et al. [14] showed the same result in cells from bovine discs using in situ hybridization and northern hybridization methods. These age-related changes indicate a decline in the metabolic activity of the disc cells with ageing, which can contribute to the lack of repair and replacement of damaged collagen fibrils.
It is interesting that BMP-2 and BMP2R-IA gene expression in the old cells are both significantly higher than that in the young cells. Takae et al. [15] found the same result using immunohistochemistry in the cervical discs of male senescence-accelerated mice aged 8, 24, and 50 weeks. Stronger BMP-2, BMP-4, BMPR-IA, BMPR-IB, and BMPR-II staining was observed in fibrous cartilaginous cells within AF of old mice aged 50 weeks. As shown in this study and other studies [4, 5] , BMP-2 can promote AF cells to synthesize a more functional disc matrix like proteoglycans and collagen II. The up-regulation of BMP-2 and its receptors in the older cells, as shown here, may be an inherent response by the cells to retard disc degeneration.
It is well known that rhBMP-2 has the capacity to make bone; it has been approved by the Food and Drug Administration (FDA) for its use in anterior interbody bone fusion in the human spine [16] . Muschik et al. [17] injected bovine bone morphogenetic protein (bBMP) into the rabbit intervertebral disc to induce anterior interbody fusion. They found bBMP induced bone formation in a dose-dependent manner. In the 10 μg group, new-bone formation was less extensive than that in the 150 μg group. However, Kim et al. [18] showed rhBMP-2 up-regulated human intervertebral disc cells chondrogenic markers aggrecan, collagen II and collagen I gene expression, but not the osteogenic marker osteocalcin gene. Yoon et al. [4] demonstrated in rat AF cells that rhBMP-2 in the 10−1000 ng/ml dose range increased aggrecan, collagen II and Sox9 genes, with a relatively low increase in the osteocalcin gene. Thus it seems that the ability of rhBMP-2 for making bone or alternatively repairing the degenerated disc is mostly dependent on the dose of growth factor selected.
In conclusion, old AF cells after rhBMP-2 treatment have a greater capacity to synthesize sGAG and express aggrecan and collagen II as compared with young AF cells
